



2025 HOT TOPIC IN BASIC &
TRANSLATIONAL SCIENCE
SMALL CELL
LUNG CANCER

SPRING 2025 | NEW YORK, NY

Abstract Timeline

November 18	Launch Abstract Submission System
January 3	Abstract Submission Deadline
January 13	Abstract Notifications

Abstract Submission Guidelines

Abstract Word Limit:	500 words in length (does not include title and authors)
Title Character Limit:	125 characters in length
Abstract Format:	Abstracts should be organized with headings: Background, Method, Results, Conclusions. Content of the abstract will be uploaded as plain text within the Abstract Submission Portal.
Tables:	No limit, each table counts as 100 words
Images:	2 maximum, each image counts as 100 words
Format(s):	Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size.
Language:	English
Fee:	No fee
Submission Limit:	No limit to the numbers of abstracts an author can submit
Number of co-authors:	No limit

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Late-Breaking Abstract (LBA) Submission: LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Authors of LBA must submit a place holder abstract through the abstract portal by July 10, 2024

Required sections for LBA place holder, which must be submitted by the January 3 deadline:

- Explanation of why the abstract qualifies as late-breaking
- Introduction
- Methods, including applicable endpoints
- Types of anticipated analysis and data to be reported

Trial in Progress: SCLC 2025 does not accept submissions of trials in progress.

Case Report: SCLC 2025 does not accept the submissions of case reports.

Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.

Topics/Tracks:

- Extensive Stage Small Cell Lung Cancer
- Early Stage Small Cell Lung Cancer
- Risk Factors, Risk Reduction & Tobacco Control
- Tumor Biology - Preclinical Biology
- Tumor Biology - Translational Biology
- Pulmonology and Staging
- Pathology and Biomarkers
- Global Health, Health Services, and Health Economics